相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) dimers for cancer therapy
John A. Hartley
EXPERT OPINION ON BIOLOGICAL THERAPY (2021)
Tumor-selective blockade of CD47 signaling with a CD47/PD-L1 bispecific antibody for enhanced anti-tumor activity and limited toxicity
Yan Wang et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)
CAR T cell therapies for patients with multiple myeloma
Lekha Mikkilineni et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors
Matthew D. Hellmann et al.
CLINICAL CANCER RESEARCH (2021)
Psoriasis: Recent progress in molecular-targeted therapies
Masaru Honma et al.
JOURNAL OF DERMATOLOGY (2021)
Development of Antibody-Based PROTACs for the Degradation of the Cell-Surface Immune Checkpoint Protein PD-L1
Adam D. Cotton et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2021)
Antibodies to watch in 2021
Helene Kaplon et al.
MABS (2021)
Tumor-targeting anti-EGFR x anti-PD1 bispecific antibody inhibits EGFR-overexpressing tumor growth by combining EGFR blockade and immune activation with direct tumor cell killing
Li Li et al.
TRANSLATIONAL ONCOLOGY (2021)
Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1+ Activated T Cells
Simon J. Dovedi et al.
CANCER DISCOVERY (2021)
Empirical and Rational Design of T Cell Receptor-Based Immunotherapies
Heather F. Jones et al.
FRONTIERS IN IMMUNOLOGY (2021)
Site-Specific Dual-Labeling of a VHH with a Chelator and a Photosensitizer for Nuclear Imaging and Targeted Photodynamic Therapy of EGFR-Positive Tumors
Emma Renard et al.
CANCERS (2021)
The PSMA-targeting Half-life Extended BiTE Therapy AMG 160 has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-resistant Prostate Cancer
Petra Deegen et al.
CLINICAL CANCER RESEARCH (2021)
Targeting a neoantigen derived from a common TP53 mutation
Emily Han-Chung Hsiue et al.
SCIENCE (2021)
Cancer immune therapy with PD-1-dependent CD137 co-stimulation provides localized tumour killing without systemic toxicity
Yunqian Qiao et al.
NATURE COMMUNICATIONS (2021)
Bispecific antibodies targeting mutant RAS neoantigens
Jacqueline Douglass et al.
SCIENCE IMMUNOLOGY (2021)
A BCMAxCD3 bispecific T cell-engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells
David J. DiLillo et al.
BLOOD ADVANCES (2021)
Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial
Paolo F. Caimi et al.
LANCET ONCOLOGY (2021)
ISB 1342: A first-in-class CD38 T cell engager for the treatment of relapsed refractory multiple myeloma.
Marie-Agnes Doucey et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
The McCAVE Trial: Vanucizumab plus mFOLFOX-6 Versus Bevacizumab plus mFOLFOX-6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC)
Johanna C. Bendell et al.
ONCOLOGIST (2020)
CD44 Promotes PD-L1 Expression and Its Tumor-Intrinsic Function in Breast and Lung Cancers
Tim Kong et al.
CANCER RESEARCH (2020)
Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Laurie H. Sehn et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma
Max S. Topp et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
Sagar Lonial et al.
LANCET ONCOLOGY (2020)
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study
Lecia Sequist et al.
LANCET ONCOLOGY (2020)
B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches
Nina Shah et al.
LEUKEMIA (2020)
Anti-ErbB2 immunotherapeutics: struggling to make better antibodies for cancer therapy
Rita De Santis
MABS (2020)
NK cells for cancer immunotherapy
Noriko Shimasaki et al.
NATURE REVIEWS DRUG DISCOVERY (2020)
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
Shanu Modi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing
Patrick J. Engelberts et al.
EBIOMEDICINE (2020)
Challenges and strategies for next-generation bispecific antibody-based antitumor therapeutics
Heliang Li et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2020)
FS222, a CD137/PD-L1 Tetravalent Bispecific Antibody, Exhibits Low Toxicity and Antitumor Activity in Colorectal Cancer Models
Matthew A. Lakins et al.
CLINICAL CANCER RESEARCH (2020)
Monobodies as enabling tools for structural and mechanistic biology
Oliver Hantschel et al.
CURRENT OPINION IN STRUCTURAL BIOLOGY (2020)
A phase I/II study of REGN5678 (Anti-PSMAxCD28, a costimulatory bispecific antibody) with cemiplimab (anti-PD-1) in patients with metastatic castration-resistant prostate cancer.
Charles G. Drake et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
A phase I study of AK112, a bispecific antibody that targets PD-1 and VEGF co-expressing T cells, in patients with advanced solid tumors.
Jermaine Coward et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Computational stabilization of T cell receptors allows pairing with antibodies to form bispecifics
Karen Froning et al.
NATURE COMMUNICATIONS (2020)
Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC
Jiyeon Yun et al.
CANCER DISCOVERY (2020)
CD137/OX40 Bispecific Antibody Induces Potent Antitumor Activity that Is Dependent on Target Coengagement
Miguel Gaspar et al.
CANCER IMMUNOLOGY RESEARCH (2020)
Recent advances of antibody drug conjugates for clinical applications
Pengxuan Zhao et al.
ACTA PHARMACEUTICA SINICA B (2020)
TCR-mimic antibody-drug conjugates targeting intracellular tumor-specific mutant antigen KRAS G12V mutation
Ying Shen et al.
ASIAN JOURNAL OF PHARMACEUTICAL SCIENCES (2020)
T cell-engaging therapies - BiTEs and beyond
Maria-Elisabeth Goebeler et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
Generation and validation of structurally defined antibody-siRNA conjugates
Alex R. Nanna et al.
NUCLEIC ACIDS RESEARCH (2020)
Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE) (vol 31, pg 79, 2020)
M. Kundranda et al.
ANNALS OF ONCOLOGY (2020)
A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma
Nancy L. Bartlett et al.
BLOOD (2020)
Treatment of muscle-invasive and advanced bladder cancer in 2020
Vaibhav G. Patel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
Phase Ib study of BI 836880, a VEGF/Ang2-blocking nanobody®, in combination with BI 754091, an anti-PD-1 antibody: Initial results in patients (pts) with solid tumours
N. Girard et al.
ANNALS OF ONCOLOGY (2020)
Safety and antitumor activity of AK104, a bispecific antibody targeting PD-1 and CTLA-4, in patients with mesothelioma which is relapsed or refractory to standard therapies
M. Millward et al.
ANNALS OF ONCOLOGY (2020)
Amivantamab (JNJ-61186372), an Fc Enhanced EGFR/cMet Bispecific Antibody, Induces Receptor Downmodulation and Antitumor Activity by Monocyte/Macrophage Trogocytosis
Smruthi Vijayaraghavan et al.
MOLECULAR CANCER THERAPEUTICS (2020)
IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy
Ting Zhou et al.
NATURE (2020)
Advances in oligonucleotide drug delivery
Thomas C. Roberts et al.
NATURE REVIEWS DRUG DISCOVERY (2020)
Antibody-Drug Conjugates for Cancer Therapy
Umbreen Hafeez et al.
MOLECULES (2020)
Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial
Nirav N. Shah et al.
NATURE MEDICINE (2020)
Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults
Robin Foa et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Bispecific Targeting of PD-1 and PD-L1 Enhances T-cell Activation and Antitumor Immunity
Helen Kotanides et al.
CANCER IMMUNOLOGY RESEARCH (2020)
Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma
Kodandaram Pillarisetti et al.
BLOOD ADVANCES (2020)
Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART Molecule
Alexey Berezhnoy et al.
CELL REPORTS MEDICINE (2020)
AFM24, a bispecific EGFR/CD16A innate cell engager with the potential to overcome resistance to current targeted treatments for EGFR-positive malignancies
Uwe Reusch et al.
CANCER RESEARCH (2020)
Preclinical development and mechanism of action studies of NM21-1480, a PD-L1/4-1BB/HSA trispecific MATCH3 therapeutic clinical candidate
Daniel Snell et al.
CANCER RESEARCH (2020)
RG7769 (PD1-TIM3), a novel heterodimeric avidity-driven T cell specific PD-1/TIM-3 bispecific antibody lacking Fc-mediated effector functions for dual checkpoint inhibition to reactivate dysfunctional T cells
Laura Laura et al.
CANCER RESEARCH (2020)
A Phase 1, Open-Label Study of MGD013, a Bispecific DART® Molecule Binding PD-1 and LAG-3 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Jie Wang et al.
BLOOD (2020)
Treatment-Free Intervals Mitigate T-Cell Exhaustion Induced By Continuous CD19xCD3-BiTE® Construct Stimulation in Vitro
Nora Zieger et al.
BLOOD (2020)
Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of Vibecotamab (XmAb14045), a CD123 x CD3 T Cell-Engaging Bispecific Antibody; Initial Results of a Phase 1 Study
Farhad Ravandi et al.
BLOOD (2020)
Mosunetuzumab Shows Promising Efficacy in Patients with Multiply Relapsed Follicular Lymphoma: Updated Clinical Experience from a Phase I Dose-Escalation Trial
Sarit E. Assouline et al.
BLOOD (2020)
Population Pharmacokinetics and Exposure-Response Analyses for Glofitamab in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R NHL): Confirmation of Efficacy and CRS Mitigation in Patients with Step-up Dosing
Nassim Djebli et al.
BLOOD (2020)
Preliminary Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Subcutaneously (SC) Administered PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Alexander M. Lesokhin et al.
BLOOD (2020)
Odronextamab (REGN1979), a Human CD20 x CD3 Bispecific Antibody, Induces Durable, Complete Responses in Patients with Highly Refractory B-Cell Non-Hodgkin Lymphoma, Including Patients Refractory to CAR T Therapy
Rajat Bannerji et al.
BLOOD (2020)
Updated Phase 1 Results of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Relapsed and/or Refractory Multiple Myeloma (RRMM)
Alfred L. Garfall et al.
BLOOD (2020)
Targeting a membrane-proximal epitope on mesothelin increases the tumoricidal activity of a bispecific antibody blocking CD47 on mesothelin-positive tumors
Eric Hatterer et al.
MABS (2020)
Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation
Lan Wu et al.
NATURE CANCER (2020)
Antibody-cytokine fusion proteins: Biopharmaceuticals with immunomodulatory properties for cancer therapy
Cornelia Hutmacher et al.
ADVANCED DRUG DELIVERY REVIEWS (2019)
A first-in-human phase 1a study of the bispecific anti-DLL4/anti-VEGF antibody navicixizumab (OMP-305B83) in patients with previously treated solid tumors
Antonio Jimeno et al.
INVESTIGATIONAL NEW DRUGS (2019)
Taking a BiTE out of ALL: blinatumomab approval for MRD-positive ALL
Emily Curran et al.
BLOOD (2019)
Targeting natural killer cells in solid tumors
Guillaume Habif et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2019)
FDA Approval: Blinatumomab for Patients with B-cell Precursor Acute Lymphoblastic Leukemia in Morphologic Remission with Minimal Residual Disease
Emily Y. Jen et al.
CLINICAL CANCER RESEARCH (2019)
89Zr-labeled Bispecific T-cell Engager AMG 211 PET Shows AMG 211 Accumulation in CD3-rich Tissues and Clear, Heterogeneous Tumor Uptake
Kirsten L. Moek et al.
CLINICAL CANCER RESEARCH (2019)
Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers
Parisa Malekzadeh et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Antibody-Drug Conjugate-Based Therapeutics: State of the Science
Michael J. Birrer et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2019)
CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape
Mohamad Hamieh et al.
NATURE (2019)
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
A. Bardia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Antibody-Cytokine Fusions: Versatile Products for the Modulation of Anticancer Immunity
Dario Neri
CANCER IMMUNOLOGY RESEARCH (2019)
Engineering and Design of Chimeric Antigen Receptors
Sonia Guedan et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2019)
Multi Targeted CAR-T Cell Therapies for B-Cell Malignancies
Nirav N. Shah et al.
FRONTIERS IN ONCOLOGY (2019)
Tumor-Localized Costimulatory T-Cell Engagement by the 4-1BB/HER2 Bispecific Antibody-Anticalin Fusion PRS-343
Marlon J. Hinner et al.
CLINICAL CANCER RESEARCH (2019)
Antibody Fragments as Potential Biopharmaceuticals for Cancer Therapy: Success and Limitations
Roman Kholodenko et al.
CURRENT MEDICINAL CHEMISTRY (2019)
Blinatumomab administered concurrently with oral tyrosine kinase inhibitor therapy is a well-tolerated consolidation strategy and eradicates measurable residual disease in adults with Philadelphia chromosome positive acute lymphoblastic leukemia
Amber C. King et al.
LEUKEMIA RESEARCH (2019)
A review of bispecific antibodies and antibody constructs in oncology and clinical challenges
Frans V. Suurs et al.
PHARMACOLOGY & THERAPEUTICS (2019)
The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation
Anne Mansson Kvarnhammar et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Antibody-Oligonucleotide Conjugates as Therapeutic, Imaging, and Detection Agents
Igor Dovgan et al.
BIOCONJUGATE CHEMISTRY (2019)
Polatuzumab Vedotin: First Global Approval
Emma D. Deeks
DRUGS (2019)
Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy
Jonathan E. Rosenberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Combination of CTLA-4 and PD-1 blockers for treatment of cancer
Anand Rotte
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
Functionally Defective T Cells After Chemotherapy of B-Cell Malignancies Can Be Activated by the Tetravalent Bispecific CD19/CD3 Antibody AFM11
Johannes Duell et al.
JOURNAL OF IMMUNOTHERAPY (2019)
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study
Kenji Tamura et al.
LANCET ONCOLOGY (2019)
Bispecific antibodies: a mechanistic review of the pipeline
Aran F. Labrijn et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial
Andreas Stahl et al.
LANCET (2019)
Antibody-drug conjugates for cancer
Cindy H. Chau et al.
LANCET (2019)
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Preliminary Safety and Anti-Tumor Activity of XmAb13676, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia
Krish Patel et al.
BLOOD (2019)
Targeting B-Cell Maturation Antigen (BCMA) with CC-93269, a 2+1 T Cell Engager, Elicits Significant Apoptosis in Diffuse Large B-Cell Lymphoma Preclinical Models
Patrick R. Hagner et al.
BLOOD (2019)
EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression
Shunli Peng et al.
MOLECULAR CANCER (2019)
Preliminary Results from a Phase 1 First-in-Human Study of AMG 673, a Novel Half-Life Extended (HLE) Anti-CD33/CD3 BiTE® (Bispecific T-Cell Engager) in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
Marion y Subklewe et al.
BLOOD (2019)
Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2:2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
Peter Westervelt et al.
BLOOD (2019)
Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985)
Zhuyu Xu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
Steven Horwitz et al.
LANCET (2019)
Bispecific applications of non-immunoglobulin scaffold binders
Sophia Hober et al.
METHODS (2019)
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Jerome Galon et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Targeting cancers through TCR-peptide/MHC interactions
Qinghua He et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Targeting the α4-α5 dimerization interface of K-RAS inhibits tumor formation in vivo
Imran Khan et al.
ONCOGENE (2019)
David vs. Goliath: The Structure, Function, and Clinical Prospects of Antibody Fragments
Adam Bates et al.
ANTIBODIES (2019)
ZW49, a HER2 targeted biparatopic antibody drug conjugate for the treatment of HER2 expressing cancers
K. J. Hamblett et al.
CANCER RESEARCH (2019)
Targeting the MHC Ligandome by Use of TCR-Like Antibodies
Lene Stokken Hoydahl et al.
ANTIBODIES (2019)
Ion Channel Targeting with Antibodies and Antibody Fragments for Cancer Diagnosis
Claudia Duranti et al.
ANTIBODIES (2019)
IgA and FcαRI: Pathological Roles and Therapeutic Opportunities
Annelot Breedveld et al.
FRONTIERS IN IMMUNOLOGY (2019)
Antibody-drug conjugates: recent advances in conjugation and linker chemistries
Kyoji Tsuchikama et al.
PROTEIN & CELL (2018)
GA101 P329GLALA, a variant of obinutuzumab with abolished ADCC, ADCP and CDC function but retained cell death induction, is as efficient as rituximab in B-cell depletion and antitumor activity
Sylvia Herter et al.
HAEMATOLOGICA (2018)
CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
Terry J. Fry et al.
NATURE MEDICINE (2018)
Next generation antibody drugs: pursuit of the 'high-hanging fruit'
Paul J. Carter et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
Cytokines in Cancer Immunotherapy
Thomas A. Waldmann
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2018)
IgG Fc engineering to modulate antibody effector functions
Xinhua Wang et al.
PROTEIN & CELL (2018)
GA101 P329GLALA, a variant of obinutuzumab with abolished ADCC, ADCP and CDC function but retained cell death induction, is as efficient as rituximab in B-cell depletion and antitumor activity
Sylvia Herter et al.
HAEMATOLOGICA (2018)
CD89-mediated recruitment of macrophages via a bispecific antibody enhances anti-tumor efficacy
Bingyu Li et al.
ONCOIMMUNOLOGY (2018)
Anticalin® Proteins as Therapeutic Agents in Human Diseases
Christine Rothe et al.
BIODRUGS (2018)
Elimination of melanoma by sortase A-generated TCR-like antibody-drug conjugates (TL-ADCs) targeting intracellular melanoma antigen MART-1
Jun Lai et al.
BIOMATERIALS (2018)
ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies
Francesca Zammarchi et al.
BLOOD (2018)
Unbiased Combinatorial Screening Identifies a Bispecific IgG1 that Potently Inhibits HER3 Signaling via HER2-Guided Ligand Blockade
Cecile A. W. Geuijen et al.
CANCER CELL (2018)
Monoclonal antibodies as immunomodulatory therapy against cancer and autoimmune diseases
Umbreen Hafeez et al.
CURRENT OPINION IN PHARMACOLOGY (2018)
Hitting the Target: How T Cells Detect and Eliminate Tumors
Anthony E. Zamora et al.
JOURNAL OF IMMUNOLOGY (2018)
Biology of IL-2 and its therapeutic modulation: Mechanisms and strategies
Suman Mitra et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2018)
Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia
Robert J. Kreitman et al.
LEUKEMIA (2018)
ABT-165, a Dual Variable Domain Immunoglobulin (DVD-Ig) Targeting DLL4 and VEGF, Demonstrates Superior Efficacy and Favorable Safety Profiles in Preclinical Models
Yingchun Li et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Characterization of ABBV-221, a Tumor-Selective EGFR-Targeting Antibody Drug Conjugate
Andrew C. Phillips et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma
J. M. Connors et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Soluble T-cell receptor design influences functional yield in an E. coli chaperone-assisted expression system
Kristin Stoen Gunnarsen et al.
PLOS ONE (2018)
CAR T cell immunotherapy for human cancer
Carl H. June et al.
SCIENCE (2018)
Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β
Yan Lan et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)
Young Kwang Chae et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
Jun Gong et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Dual blockade of PD-L1 and LAG-3 with FS118, a unique bispecific antibody, induces CD8+T-cell activation and modulates the tumor microenvironment to promote antitumor immune responses
Matthew Kraman et al.
CANCER RESEARCH (2018)
HPN424, a half-life extended, PSMA/CD3-specific TriTAC for the treatment of metastatic prostate cancer
Bryan Lemon et al.
CANCER RESEARCH (2018)
GBR1302: Effect of CD3-HER2, a bispecific T cell engager antibody, in trastuzumab-resistant cancers.
Jonathan Back et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Structural and functional characterization of MBS301, an afucosylated bispecific anti-HER2 antibody
Sijia Huang et al.
MABS (2018)
A novel human IL-2 mutein with minimal systemic toxicity exerts greater antitumor efficacy than wild-type IL-2
Xi Chen et al.
CELL DEATH & DISEASE (2018)
A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma
Wan-Hong Zhao et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma
Ranjana Advani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Isolation and characterization of NY-ESO-1-specific T cell receptors restricted on various MHC molecules
Michael T. Bethune et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors
Manuel Hidalgo et al.
CLINICAL CANCER RESEARCH (2018)
Trispecific killer engager CD16xIL15xCD33 potently induces NK cell activation and cytotoxicity against neoplastic mast cells
Hyun Don Yun et al.
BLOOD ADVANCES (2018)
Immunotherapy targeting 4-1BB: mechanistic rationale, clinical results, and future strategies
Cariad Chester et al.
BLOOD (2018)
Antibody-siRNA conjugates: drugging the undruggable for anti-leukemic therapy
Jogender Tushir-Singh
EXPERT OPINION ON BIOLOGICAL THERAPY (2017)
Inhibition of RAS function through targeting an allosteric regulatory site
Russell Spencer-Smith et al.
NATURE CHEMICAL BIOLOGY (2017)
Sacituzumab govitecan: an antibody-drug conjugate
Sheena Sahota et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2017)
Polyfunctional response by ImmTAC (IMCgp100) redirected CD8+ and CD4+ T cells
Caroline Boudousquie et al.
IMMUNOLOGY (2017)
A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I antigens
Aaron Y. Chang et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study
Kathleen N. Moore et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study
Giovanni Martinelli et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
H. Miles Prince et al.
LANCET (2017)
Selective Blockade of the Ubiquitous Checkpoint Receptor CD47 Is Enabled by Dual-Targeting Bispecific Antibodies
Elie Dheilly et al.
MOLECULAR THERAPY (2017)
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Hagop Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Localized CD47 blockade enhances immunotherapy for murine melanoma
Jessica R. Ingram et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Monobodies and other synthetic binding proteins for expanding protein science
Fern Sha et al.
PROTEIN SCIENCE (2017)
Affibody Molecules in Biotechnological and Medical Applications
Stefan Stahl et al.
TRENDS IN BIOTECHNOLOGY (2017)
Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics
Peter Bannas et al.
FRONTIERS IN IMMUNOLOGY (2017)
Overcoming resistance to HER2-targeted therapy with a novel HER2/CD3 bispecific antibody
Andres Lopez-Albaitero et al.
ONCOIMMUNOLOGY (2017)
tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines
Dina Schneider et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Antibody-cytokine fusion proteins for improving efficacy and safety of cancer therapy
Zahra Valedkarimi et al.
BIOMEDICINE & PHARMACOTHERAPY (2017)
Inotuzumab Ozogamicin: First Global Approval
Yvette N. Lamb
DRUGS (2017)
Preclinical evaluation of MCLA-158: A bispecific antibody targeting LGR5 and EGFR using patient-derived colon carcinoma organoids
Rob Roovers et al.
CANCER RESEARCH (2017)
RAS Proteins and Their Regulators in Human Disease
Dhirendra K. Simanshu et al.
CELL (2017)
Translation and Clinical Development of Bispecific T-cell Engaging Antibodies for Cancer Treatment
T. Yuraszeck et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
Anticalins directed against the fibronectin extra domain B as diagnostic tracers for glioblastomas
Valerie Albrecht et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
Antibody-coupled siRNA as an efficient method for in vivo mRNA knockdown
Nicole Baeumer et al.
NATURE PROTOCOLS (2016)
Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors
Qiong J. Wang et al.
CANCER IMMUNOLOGY RESEARCH (2016)
T cell receptor mimic antibodies for cancer therapy
Leonid Dubrovsky et al.
ONCOIMMUNOLOGY (2016)
Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy
Rebecca Gardner et al.
BLOOD (2016)
Origin and Role of a Subset of Tumor-Associated Neutrophils with Antigen-Presenting Cell Features in Early-Stage Human Lung Cancer
Sunil Singhal et al.
CANCER CELL (2016)
A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung Tumors
Sheri L. Moores et al.
CANCER RESEARCH (2016)
Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models
Pia M. Challita-Eid et al.
CANCER RESEARCH (2016)
A Randomized Phase II/III Study of Naptumomab Estafenatox plus IFNα versus IFNα in Renal Cell Carcinoma: Final Analysis with Baseline Biomarker Subgroup and Trend Analysis
Robert E. Hawkins et al.
CLINICAL CANCER RESEARCH (2016)
A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors
Marina Bacac et al.
CLINICAL CANCER RESEARCH (2016)
IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function
Daniel A. Vallera et al.
CLINICAL CANCER RESEARCH (2016)
DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1
Yusuke Ogitani et al.
CLINICAL CANCER RESEARCH (2016)
In Vivo Fluorescence Imaging of the Activity of CEA TCB, a Novel T-Cell Bispecific Antibody, Reveals Highly Specific Tumor Targeting and Fast Induction of T-Cell-Mediated Tumor Killing
Steffi Lehmann et al.
CLINICAL CANCER RESEARCH (2016)
Immunocytokines for cancer treatment: past, present and future
Dario Neri et al.
CURRENT OPINION IN IMMUNOLOGY (2016)
Opportunities and challenges for TCR mimic antibodies in cancer therapy
Aaron Y. Chang et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2016)
Allosteric Inhibition of Bcr-Abl Kinase by High Affinity Monobody Inhibitors Directed to the Src Homology 2 (SH2)-Kinase Interface
John Wojcik et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2016)
Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial
Sergio Amadori et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia
Arend von Stackelberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Development of antibody-siRNA conjugate targeted to cardiac and skeletal muscles
Tsukasa Sugo et al.
JOURNAL OF CONTROLLED RELEASE (2016)
CODV-Ig, a universal bispecific tetravalent and multifunctional immunoglobulin format for medical applications
Anke Steinmetz et al.
MABS (2016)
MOR209/ES414, a Novel Bispecific Antibody Targeting PSMA for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Gabriela Hernandez-Hoyos et al.
MOLECULAR CANCER THERAPEUTICS (2016)
RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis
Peter Brunker et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
Giampaolo Bianchini et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
Hagop M. Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Selective targeting of IL-2 to NKG2D bearing cells for improved immunotherapy
Reza Ghasemi et al.
NATURE COMMUNICATIONS (2016)
Immune-mediated liver injury of the cancer therapeutic antibody catumaxomab targeting EpCAM, CD3 and Fcγ receptors
Juergen Borlak et al.
ONCOTARGET (2016)
T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells
Eugenia Zah et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Immunoprofiling of Normal Human Donor Blood Identified Potential Pharmacodynamic Markers for JNJ-63709178 (CD123xCD3) Duobody® Antibody Treatment
Alexander Babich et al.
BLOOD (2016)
Designed Ankyrin Repeat Proteins (DARPins): Binding Proteins for Research, Diagnostics, and Therapy
Andreas Plueckthun
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 55 (2015)
A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma
Achim Rothe et al.
BLOOD (2015)
Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic NanobodyA® targeting the DR5 receptor
Kyriakos P. Papadopoulos et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
Phase I Study of a Bispecific Ligand-Directed Toxin Targeting CD22 and CD19 (DT2219) for Refractory B-cell Malignancies
Veronika Bachanova et al.
CLINICAL CANCER RESEARCH (2015)
Cancer immunotherapy: harnessing the immune system to battle cancer
Yiping Yang
JOURNAL OF CLINICAL INVESTIGATION (2015)
Immune Checkpoint Blockade in Cancer Therapy
Michael A. Postow et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy
Jingjing Wu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
Max S. Topp et al.
LANCET ONCOLOGY (2015)
Inhibition of angiogenesis in human endothelial cell using VEGF specific nanobody
Fatemeh Kazemi-Lomedasht et al.
MOLECULAR IMMUNOLOGY (2015)
Case Report of a Fatal Serious Adverse Event Upon Administration of T Cells Transduced With a MART-1-specific T-cell Receptor
Joost H. van den Berg et al.
MOLECULAR THERAPY (2015)
Nanobody-based cancer therapy of solid tumors
Marta Kijanka et al.
NANOMEDICINE (2015)
Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1
Tao Dao et al.
NATURE BIOTECHNOLOGY (2015)
Agonists of Co-stimulation in Cancer Immunotherapy Directed Against CD137, 0X40, GITR, CD27, CD28, and ICOS
Miguel F. Sanmamed et al.
SEMINARS IN ONCOLOGY (2015)
Exploiting light chains for the scalable generation and platform purification of native human bispecific IgG
Nicolas Fischer et al.
NATURE COMMUNICATIONS (2015)
PIK3CAH1047R-Mediated Multipotency Underlies Breast Tumor Heterogeneity
[Anonymous]
CANCER DISCOVERY (2015)
Immunological response and overall survival in a subset of advanced renal cell carcinoma patients from a randomized phase 2/3 study of naptumomab estafenatox plus IFN-α versus IFN-α
Eyad Elkord et al.
ONCOTARGET (2015)
Neoepitopes of Cancers: Looking Back, Looking Ahead
Pramod K. Srivastava
CANCER IMMUNOLOGY RESEARCH (2015)
Systematic evaluation of antibody-mediated siRNA delivery using an industrial platform of THIOMAB-siRNA conjugates
Trinna L. Cuellar et al.
NUCLEIC ACIDS RESEARCH (2015)
Building better monoclonal antibody-based therapeutics
George J. Weiner
NATURE REVIEWS CANCER (2015)
Targeting hepatocyte growth factor receptor (Met) positive tumor cells using internalizing nanobody-decorated albumin nanoparticles
Raimond Heukers et al.
BIOMATERIALS (2014)
Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML
George S. Laszlo et al.
BLOOD (2014)
A TCR-mimic antibody to WT1 bypasses tyrosine kinase inhibitor resistance in human BCR-ABL+ leukemias
Leonid Dubrovsky et al.
BLOOD (2014)
Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma
Yu-Tzu Tai et al.
BLOOD (2014)
CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets
Michelle K. Gleason et al.
BLOOD (2014)
Trastuzumab emtansine: mechanisms of action and drug resistance
Mark Barok et al.
BREAST CANCER RESEARCH (2014)
Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
Rakesh K. Jain
CANCER CELL (2014)
Trastuzumab Emtansine: A Novel Antibody-Drug Conjugate for HER2-Positive Breast Cancer
Ian Krop et al.
CLINICAL CANCER RESEARCH (2014)
Therapeutic Efficacy of an Fc-Enhanced TCR-like Antibody to the Intracellular WT1 Oncoprotein
Nicholas Veomett et al.
CLINICAL CANCER RESEARCH (2014)
Abundant in vitro expression of the oncofetal ED-B-containing fibronectin translates into selective pharmacodelivery of 131I-L19SIP in a prostate cancer patient
Ricarda Locher et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2014)
A novel tetravalent bispecific TandAb (CD30/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells
Uwe Reusch et al.
MABS (2014)
Selection of high-affinity Centyrin FN3 domains from a simple library diversified at a combination of strand and loop positions
Michael D. Diem et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2014)
Anti-melanoma activity of T cells redirected with a TCR-like chimeric antigen receptor
Ge Zhang et al.
SCIENTIFIC REPORTS (2014)
Combined Targeting of Costimulatory (OX40) and Coinhibitory (CTLA-4) Pathways Elicits Potent Effector T Cells Capable of Driving Robust Antitumor Immunity
William L. Redmond et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Nanobodies: Natural Single-Domain Antibodies
Serge Muyldermans
ANNUAL REVIEW OF BIOCHEMISTRY, VOL 82 (2013)
A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia
Stephen H. Petersdorf et al.
BLOOD (2013)
PSMA specific single chain antibody-mediated targeted knockdown of Notch1 inhibits human prostate cancer cell proliferation and tumor growth
Yansheng Su et al.
CANCER LETTERS (2013)
Dual Targeting of EGFR and HER3 with MEHD7945A Overcomes Acquired Resistance to EGFR Inhibitors and Radiation
Shyhmin Huang et al.
CANCER RESEARCH (2013)
Ang-2-VEGF-A CrossMab, a Novel Bispecific Human IgG1 Antibody Blocking VEGF-A and Ang-2 Functions Simultaneously, Mediates Potent Antitumor, Antiangiogenic, and Antimetastatic Efficacy
Yvonne Kienast et al.
CLINICAL CANCER RESEARCH (2013)
A phase I dose-escalation study of the immunocytokine EMD 521873 (Selectikine) in patients with advanced solid tumours
Silke Gillessen et al.
EUROPEAN JOURNAL OF CANCER (2013)
Llama-derived Single Variable Domains (Nanobodies) Directed against Chemokine Receptor CXCR7 Reduce Head and Neck Cancer Cell Growth in Vivo
David Maussang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Targeting breast carcinoma with radioiodinated anti-HER2 Nanobody
Marek Pruszynski et al.
NUCLEAR MEDICINE AND BIOLOGY (2013)
Targeting the Intracellular WT1 Oncogene Product with a Therapeutic Human Antibody
Tao Dao et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
The Basic Principles of Chimeric Antigen Receptor Design
Michel Sadelain et al.
CANCER DISCOVERY (2013)
Defining the expression hierarchy of latent T-cell epitopes in Epstein-Barr virus infection with TCR-like antibodies
Adrian Chong Nyi Sim et al.
SCIENTIFIC REPORTS (2013)
TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy
Zakaria Grada et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2013)
Designed Ankyrin Repeat Proteins (DARPins) as Novel Isoform-Specific Intracellular Inhibitors of c-Jun N-Terminal Kinases
Petra Parizek et al.
ACS CHEMICAL BIOLOGY (2012)
Mechanism of action of therapeutic monoclonal antibodies: Promises and pitfalls of in vitro and in vivo assays
Josee Golay et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2012)
Antibody-cytokine fusion proteins
Roland E. Kontermann
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2012)
scFv Antibody: Principles and Clinical Application
Zuhaida Asra Ahmad et al.
CLINICAL & DEVELOPMENTAL IMMUNOLOGY (2012)
Interleukin 2 in Cancer Therapy
G. K. Antony et al.
CURRENT MEDICINAL CHEMISTRY (2012)
Monoclonal antibody therapeutics: history and future
Nicholas A. P. S. Buss et al.
CURRENT OPINION IN PHARMACOLOGY (2012)
Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study
Barbara Pro et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
Anas Younes et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Therapeutic Potential of Amanitin-Conjugated Anti-Epithelial Cell Adhesion Molecule Monoclonal Antibody Against Pancreatic Carcinoma
Gerhard Moldenhauer et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
Regression of Human Prostate Cancer Xenografts in Mice by AMG 212/BAY2010112, a Novel PSMA/CD3-Bispecific BiTE Antibody Cross-Reactive with Non-Human Primate Antigens
Matthias Friedrich et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Antitumor Activity of a Novel Bispecific Antibody That Targets the ErbB2/ErbB3 Oncogenic Unit and Inhibits Heregulin-Induced Activation of ErbB3
Charlotte F. McDonagh et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Bispecific and Trispecific Killer Cell Engagers Directly Activate Human NK Cells through CD16 Signaling and Induce Cytotoxicity and Cytokine Production
Michelle K. Gleason et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
Sylvie Castaigne et al.
LANCET (2012)
Generation and characterization of a functional Nanobody against the vascular endothelial growth factor receptor-2; angiogenesis cell receptor
Mandi Behdani et al.
MOLECULAR IMMUNOLOGY (2012)
Brentuximab vedotin
Niels W. C. J. van de Donk et al.
MABS (2012)
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Sunil Verma et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Targeted Delivery of PLK1-siRNA by ScFv Suppresses Her2+ Breast Cancer Growth and Metastasis
Yan-dan Yao et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
The role of interleukin-2 during homeostasis and activation of the immune system
Onur Boyman et al.
NATURE REVIEWS IMMUNOLOGY (2012)
Targeting the SH2-Kinase Interface in Bcr-Abl Inhibits Leukemogenesis
Florian Grebien et al.
CELL (2011)
Antibody-Drug Conjugates of Calicheamicin Derivative: Gemtuzumab Ozogamicin and Inotuzumab Ozogamicin
Alejandro D. Ricart
CLINICAL CANCER RESEARCH (2011)
A Low-Toxicity IL-2-Based Immunocytokine Retains Antitumor Activity Despite Its High Degree of IL-2 Receptor Selectivity
Stephen D. Gillies et al.
CLINICAL CANCER RESEARCH (2011)
Antibody-Radionuclide Conjugates for Cancer Therapy: Historical Considerations and New Trends
Martina Steiner et al.
CLINICAL CANCER RESEARCH (2011)
Facile labelling of an anti-epidermal growth factor receptor Nanobody with 68Ga via a novel bifunctional desferal chelate for immuno-PET
Maria J. W. D. Vosjan et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2011)
Trastuzumab-DM1: Building a Chemotherapy-Free Road in the Treatment of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
Steven J. Isakoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Bispecific Antibodies for Cancer Immunotherapy
Dafne Müller et al.
BIODRUGS (2010)
A recombinant trispecific single-chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting
Markus Kuegler et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy
Diane Seimetz et al.
CANCER TREATMENT REVIEWS (2010)
Regulation of Antitumor Immune Responses by the IL-12 Family Cytokines, IL-12, IL-23, and IL-27
Mingli Xu et al.
CLINICAL & DEVELOPMENTAL IMMUNOLOGY (2010)
Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate
Nicole M. Okeley et al.
CLINICAL CANCER RESEARCH (2010)
Direct visualization of the dynamics of antigen presentation in human cells infected with cytomegalovirus revealed by antibodies mimicking TCR specificity
Oryan Makler et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2010)
Use of GM-CSF as an adjuvant with cancer vaccines: beneficial or detrimental?
Kevin S. Clive et al.
EXPERT REVIEW OF VACCINES (2010)
Breaking down the barriers: siRNA delivery and endosome escape
Monika Dominska et al.
JOURNAL OF CELL SCIENCE (2010)
Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer
David Jackman et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Structural and functional characterization of the trifunctional antibody catumaxomab
Dirk Chelius et al.
MABS (2010)
Development trends for human monoclonal antibody therapeutics
Aaron L. Nelson et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas.
Anas Younes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Therapeutic antibodies: successes, limitations and hopes for the future
Patrick Chames et al.
BRITISH JOURNAL OF PHARMACOLOGY (2009)
Development trends for therapeutic antibody fragments
Aaron L. Nelson et al.
NATURE BIOTECHNOLOGY (2009)
Single domain antibodies: promising experimental and therapeutic tools in infection and immunity
Janusz Wesolowski et al.
MEDICAL MICROBIOLOGY AND IMMUNOLOGY (2009)
Intracellular Assembly and Trafficking of MHC Class I Molecules
Julie G. Donaldson et al.
TRAFFIC (2009)
Antitumor activity of immunotoxins with T-cell receptor-like specificity against human melanoma xenografts
Eynav Klechevsky et al.
CANCER RESEARCH (2008)
Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines
Franz O. Smith et al.
CLINICAL CANCER RESEARCH (2008)
Imaging of HER-2 Overexpression in Tumors for Guiding Therapy
V. Tolmachev
CURRENT PHARMACEUTICAL DESIGN (2008)
Alternative binding proteins:: Affibody binding proteins developed from a small three-helix bundle scaffold
Per-Ake Nygren
FEBS JOURNAL (2008)
Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology
Bernard M. Tijink et al.
MOLECULAR CANCER THERAPEUTICS (2008)
SPECT imaging with 99mTc-labeled EGFR-specific nanobody for in vivo monitoring of EGFR expression
Lieven Huang et al.
MOLECULAR IMAGING AND BIOLOGY (2008)
Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members
D. L. Wheeler et al.
ONCOGENE (2008)
Paul Ehrlich's magic bullet concept: 100 years of progress
Klaus Strebhardt et al.
NATURE REVIEWS CANCER (2008)
Properties, production, and applications of camelid single-domain antibody fragments
M. M. Harmsen et al.
APPLIED MICROBIOLOGY AND BIOTECHNOLOGY (2007)
The antibody-mediated targeted delivery of interleukin-15 and GM-CSF to the tumor neovasculature inhibits tumor growth and metastasis
Manuela Kaspar et al.
CANCER RESEARCH (2007)
Selective gene silencing in activated leukocytes by targeting siRNAs to the integrin lymphocyte function-associated antigen-1
Dan Peer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group
A-L Taksin et al.
LEUKEMIA (2007)
Improved human T-cell responses against synthetic HLA-0201 analog peptides derived from the WT1 oncoprotein
J. Pinilla-Ibarz et al.
LEUKEMIA (2006)
An engineered antibody-interleukin-12 fusion protein with enhanced tumor vascular targeting properties
Verena Gafner et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer
Tracy R. Daniels et al.
CLINICAL IMMUNOLOGY (2006)
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome
Jerom Galon et al.
SCIENCE (2006)
Tumor Imaging using a picomolar affinity HER2 binding affibody molecule
A Orlova et al.
CANCER RESEARCH (2006)
A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: A study of the Children's Oncology Group
KL Osenga et al.
CLINICAL CANCER RESEARCH (2006)
Interleukin-12 induces a Th1-like response to Burkholderia mallei and limited protection in BALB/c mice
K Amemiya et al.
VACCINE (2006)
Antibody repertoire development in camelids
E De Genst et al.
DEVELOPMENTAL AND COMPARATIVE IMMUNOLOGY (2006)
Engineered vascular-targeting antibody-interferon-γ fusion protein for cancer therapy
C Ebbinghaus et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors
EW Song et al.
NATURE BIOTECHNOLOGY (2005)
A bispecific recombinant immunotoxin, DT2219, targeting human CD19 and CD22 receptors in a mouse xenograft model of B-cell leukemia/lymphoma
DA Vallera et al.
CLINICAL CANCER RESEARCH (2005)
Nanobodies as novel agents for cancer therapy
H Revets et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2005)
Fast and faster:: A designed variant of the B-domain of protein A folds in 3 μsec
P Arora et al.
PROTEIN SCIENCE (2004)
HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells
G Liu et al.
CANCER RESEARCH (2004)
Binding proteins from alternative scaffolds
PÅ Nygren et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2004)
Selection and characterization of HER2/neu-binding affibody ligands
M Wikman et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2004)
High-affinity binders selected from designed ankyrin repeat protein libraries
HK Binz et al.
NATURE BIOTECHNOLOGY (2004)
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer
L Zhang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Duocalins: Engineered ligand-binding proteins with dual specificity derived from the lipocalin fold
S Schlehuber et al.
BIOLOGICAL CHEMISTRY (2001)
Cytokines and immune response in the tumor microenvironment
S Mocellin et al.
JOURNAL OF IMMUNOTHERAPY (2001)
Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells
VHJ van der Velden et al.
BLOOD (2001)
Role of tumor-host interactions in interstitial diffusion of macromolecules: Cranial vs. subcutaneous tumors
A Pluen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Recognition of antigens by single domain antibody fragments: the superfluous luxury of paired domains
S Muyldermans et al.
TRENDS IN BIOCHEMICAL SCIENCES (2001)
Design and application of diabodies, triabodies and tetrabodies for cancer targeting
A Todorovska et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2001)
Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells
MJ Jo et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
A Drosophila mechanosensory transduction channel
RG Walker et al.
SCIENCE (2000)
分享论文
